Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Ready for the next step.

<< Previous

Bullboard Posts

Next >>

Comment by askretkaon Nov 20, 2022 9:58pm

229 Views

Post# 35114389

RE:RE:Ready for the next step.

CAR-T study by Dr Vile at Mayo Clinic came from Dr. Vile looking at AWARE-1 data early on, that was mentioned by Matt in a quarterly webcast over a year ago. So it might be another reason that Roche would go for CAR-T as well because the experiment was a spin off from their AWARE-1 study and they have the data and are more AWARE of the potential. Pun intended Cheers!!!!!!!!!!!

<< Previous

Bullboard Posts

Next >>

The long-term forecast for lithium stocks in 2024